Companies hope to challenge traiblazers Novartis and Kite.
But rival Juno finally gives up on lead therapy.
Novartis’ head of drug development talks about its stake in CAR-T immunotherapy. These cell therapies are set to transform treatment of blood cancers – but questions about safety, manufacturing and cost versus clinical value remain
Evaluate predicts sales could approach $8bn if approved.
Drug tops list compiled by Evaluate Pharma
California’s Kite strikes deals with Fosun and Daiichi Sankyo.